Currently Enrolling

HIV Trials

Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

GS-US-200-4072 · HIV Trial · Opened 11/14/2018

Major Inclusion/Exclusion Criteria

  1. HIV Naïve or off ART for > 12 weeks
  2. Integrase Naive
  3. HIV RNA > 10,000 but < 400,000 copies
  4. Absolute CD4 > 200
  5. GFR > 70
  6. Willing to start Biktarvy on day 10
  7. No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor

Read more

Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

GS-US-200-4072 · HIV Trial · Opened 11/14/2018

Major Inclusion/Exclusion Criteria

  1. HIV Naïve or off ART for > 12 weeks
  2. Integrase Naive
  3. HIV RNA > 10,000 but < 400,000 copies
  4. Absolute CD4 > 200
  5. GFR > 70
  6. Willing to start Biktarvy on day 10
  7. No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor

Read more

Safety, Pharmacokinetics, and Antiviral Activity of GS-6207 Administered Subcutaneously in HIV-1 Infected Adults

GS-US-200-4072 · HIV Trial · Opened 11/14/2018

Major Inclusion/Exclusion Criteria

  1. HIV Naïve or off ART for > 12 weeks
  2. Integrase Naive
  3. HIV RNA > 10,000 but < 400,000 copies
  4. Absolute CD4 > 200
  5. GFR > 70
  6. Willing to start Biktarvy on day 10
  7. No medications taken within 42 days prior to start of the study drug without prior approval from Sponsor

Read more

HSV Trials

No trials found.

Other Trials

No trials found.